v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

MICROBIAL PROFILE AND ANTIBIOTIC SUSCEPTIBILITY TREND IN POSTOPERATIVE ENDOPHTHALMITIS

AUTHORS:

Dr Hira Zarqoon Javed, Dr Hafsa Butter, Dr Sabreena Hafeez

ABSTRACT:

Introduction: Postoperative endophthalmitis is considered the most common form of endophthalmitis, and mostly occurs after cataract surgeries and intravitreal injections with reported incidence rates ranging from 0.012% to 1.3% and 0.016% to 0.053% respectively. Objectives: The main objective of the study is to analyse the microbial profile and antibiotic susceptibility trend in postoperative endophthalmitis. Material and methods: This descriptive study was conducted in Rawalpindi Medical University, Rawalpindi during January 2019 to October 2019. A case of endophthalmitis was diagnosed clinically as per the institute protocol. A detailed history of pain, vision loss, redness, duration of symptoms and their timeline from any ocular insult, any recent intraocular surgery, any trauma, any ocular surface infection, or presence of any non-ocular infective source in the body was noted. Results: The data was collected from 200 patients. Among the 41 gram-positive organisms identified, overall sensitivities noted were vancomycin 100%, gentamicin 91.5%, amikacin 100% ciprofloxacin 68%, chloramphenicol 100%, and tetracycline 84.6%. Among the 55 gramnegative organisms identified, overall sensitivities noted were ciprofloxacin 52.9%, ofloxacin 66.6%, ceftazidime 91.8%, amikacin 100%, tobramycin 100% imipenem 91.6%, gentamicin 81.2% and tetracycline 75%. Conclusion: It is concluded that Pseudomonas spp. and CoNS were the most frequently identified cause of endophthalmitis. Vancomycin and ceftazidime seemed to be excellent empirical antibiotics for treating postoperative endophthalmitis.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.